Literature DB >> 10215509

Effects of chronic administration of interferon alpha A/D on serotonergic receptors in rat brain.

S Abe1, T Hori, T Suzuki, A Baba, H Shiraishi, T Yamamoto.   

Abstract

The effects of chronic administration of interferon (IFN; recombinant human IFN-alphaA/D) on serotonergic binding sites in rat brain were investigated. IFN was injected daily for 2 weeks at a dose of 100000 I.U./kg, (i.p.) in male Wistar rats. IFN did not alter either [3H]ketanserin binding to 5-HT2A receptors or [3H]paroxetine binding to 5-HT transporters. Scatchard analysis of [3H]8-hydroxy-dipropylaminotetraline (8-OH-DPAT) binding to 5-HT1A receptors demonstrated the presence of high- and low-affinity binding sites in both treatment and control groups. IFN significantly increased both Kd and Bmax measures of [3H]8-OH-DPAT binding at low-affinity binding sites, but not at the high-affinity sites. These results suggest that IFN affects the low-affinity 5-HT1A receptors sites and may be involved in the development of IFN-induced psychiatric disturbances.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10215509     DOI: 10.1023/a:1020929415443

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  37 in total

1.  Interferon crosses blood-cerebrospinal fluid barrier in monkeys.

Authors:  D V Habif; R Lipton; K Cantell
Journal:  Proc Soc Exp Biol Med       Date:  1975-05

2.  Human recombinant interferon alpha inhibits naloxone binding to rat brain membranes.

Authors:  R A Menzies; R Patel; N R Hall; M P O'Grady; S E Rier
Journal:  Life Sci       Date:  1992       Impact factor: 5.037

3.  Interferon-alpha-2-induced stimulation of ACTH and cortisol secretion in man.

Authors:  H Müller; E Hammes; C Hiemke; G Hess
Journal:  Neuroendocrinology       Date:  1991-11       Impact factor: 4.914

4.  Positron emission tomography measurement of cerebral metabolic correlates of tryptophan depletion-induced depressive relapse.

Authors:  J D Bremner; R B Innis; R M Salomon; L H Staib; C K Ng; H L Miller; R A Bronen; J H Krystal; J Duncan; D Rich; L H Price; R Malison; H Dey; R Soufer; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1997-04

5.  Chronic antidepressant exposure enhances 5-hydroxytryptamine7 receptor-mediated cyclic adenosine monophosphate accumulation in rat frontocortical astrocytes.

Authors:  M Shimizu; A Nishida; H Zensho; S Yamawaki
Journal:  J Pharmacol Exp Ther       Date:  1996-12       Impact factor: 4.030

6.  Heterogeneity of cortical and hippocampal 5-HT1A receptors: a reappraisal of homogenate binding with 8-[3H]hydroxydipropylaminotetralin.

Authors:  E K Nénonéné; F Radja; M Carli; L Grondin; T A Reader
Journal:  J Neurochem       Date:  1994-05       Impact factor: 5.372

7.  Psychiatric complications of long-term interferon alfa therapy.

Authors:  P F Renault; J H Hoofnagle; Y Park; K D Mullen; M Peters; D B Jones; V Rustgi; E A Jones
Journal:  Arch Intern Med       Date:  1987-09

8.  Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists.

Authors:  J S Sprouse; G K Aghajanian
Journal:  Synapse       Date:  1987       Impact factor: 2.562

9.  Plasma and tissue pharmacokinetics of human interferon-alpha in the rat after its intravenous administration.

Authors:  N H Greig; T T Soncrant; K M Wozniak; S I Rapoport
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

10.  Cerebral interferon entry in mice after osmotic alteration of blood-brain barrier.

Authors:  M Wiranowska; T C Wilson; K Thompson; L D Prockop
Journal:  J Interferon Res       Date:  1989-06
View more
  15 in total

1.  Fluoxetine disposition in patients with chronic hepatitis C treated with interferon-α.

Authors:  Mario Furlanut; Giorgio Soardo; Debora Donnini; Leonardo Sechi; Loretta Franceschi
Journal:  Clin Pharmacokinet       Date:  2010-11       Impact factor: 6.447

Review 2.  Inflammation-associated depression: from serotonin to kynurenine.

Authors:  Robert Dantzer; Jason C O'Connor; Marcus A Lawson; Keith W Kelley
Journal:  Psychoneuroendocrinology       Date:  2010-10-30       Impact factor: 4.905

3.  Risk for depression during interferon-alpha treatment is affected by the serotonin transporter polymorphism.

Authors:  Francis E Lotrich; Robert E Ferrell; Mordechai Rabinovitz; Bruce G Pollock
Journal:  Biol Psychiatry       Date:  2008-09-18       Impact factor: 13.382

Review 4.  Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications.

Authors:  J C Felger; F E Lotrich
Journal:  Neuroscience       Date:  2013-05-03       Impact factor: 3.590

Review 5.  Inflammatory cytokine-associated depression.

Authors:  Francis E Lotrich
Journal:  Brain Res       Date:  2014-07-05       Impact factor: 3.252

6.  The role of indoleamine 2,3-dioxygenase (IDO) in the pathophysiology of interferon-alpha-induced depression.

Authors:  Marieke C Wichers; Michael Maes
Journal:  J Psychiatry Neurosci       Date:  2004-01       Impact factor: 6.186

7.  Psychiatric clearance for patients started on interferon-alpha-based therapies.

Authors:  Francis E Lotrich
Journal:  Am J Psychiatry       Date:  2013-06       Impact factor: 18.112

Review 8.  Inflammation: a mechanism of depression?

Authors:  Qiu-Qin Han; Jin Yu
Journal:  Neurosci Bull       Date:  2014-05-16       Impact factor: 5.203

9.  Major depression during interferon-alpha treatment: vulnerability and prevention.

Authors:  Francis E Lotrich
Journal:  Dialogues Clin Neurosci       Date:  2009       Impact factor: 5.986

Review 10.  Major Depression: One Brain, One Disease, One Set of Intertwined Processes.

Authors:  Elena V Filatova; Maria I Shadrina; Petr A Slominsky
Journal:  Cells       Date:  2021-05-21       Impact factor: 6.600

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.